- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapy in Melanoma and Mechanisms of Resistance
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 13, Pages 4576
Publisher
MDPI AG
Online
2020-06-29
DOI
10.3390/ijms21134576
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting complex, adaptive responses in melanoma therapy
- (2020) Phil Cheng et al. CANCER TREATMENT REVIEWS
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
- (2020) Axel Hauschild et al. EUROPEAN JOURNAL OF CANCER
- Pan-cancer analysis of whole genomes
- (2020) NATURE
- A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
- (2020) Yangzi Tian et al. MEDICAL SCIENCE MONITOR
- Current Advances in the Treatment of BRAF-Mutant Melanoma
- (2020) Hima Patel et al. Cancers
- Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis
- (2020) Yosuke Yamamoto et al. Cancer Medicine
- Nothing Is yet Set in (Hi)stone: Novel Post-Translational Modifications Regulating Chromatin Function
- (2020) Jennifer C. Chan et al. TRENDS IN BIOCHEMICAL SCIENCES
- Many ways to resistance: How melanoma cells evade targeted therapies
- (2019) Ines Kozar et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- MITF—the first 25 years
- (2019) Colin R. Goding et al. GENES & DEVELOPMENT
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
- (2019) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
- (2019) Daniël A. Lionarons et al. CANCER CELL
- Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations
- (2019) Brian D. Lehmann et al. MOLECULAR CANCER RESEARCH
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Oncogenic BRAF: Past, Present, and Future
- (2019) Zaman et al. Cancers
- Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
- (2019) Khaliq et al. Cancers
- 1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
- (2019) J S Weber et al. ANNALS OF ONCOLOGY
- BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
- (2018) Jaquelyn N. Sanchez et al. DRUGS
- Ultraviolet light and melanoma
- (2018) Sarah Craig et al. JOURNAL OF PATHOLOGY
- Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
- (2018) Anthony W. Tolcher et al. MOLECULAR CANCER THERAPEUTICS
- BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
- (2018) Jacek Mackiewicz et al. Wspolczesna Onkologia-Contemporary Oncology
- A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor
- (2018) Jiawan Wang et al. Cancer Discovery
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
- (2018) Thomas Strub et al. Nature Communications
- 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
- (2018) P A Ascierto et al. ANNALS OF ONCOLOGY
- An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
- (2018) James Larkin et al. EUROPEAN JOURNAL OF CANCER
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
- (2018) Michael J. Vido et al. Cell Reports
- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
- (2017) Xian Chan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The NF1 gene in tumor syndromes and melanoma
- (2017) Maija Kiuru et al. LABORATORY INVESTIGATION
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Pathways from senescence to melanoma: focus on MITF sumoylation
- (2017) J Leclerc et al. ONCOGENE
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- BRAF inhibitors: resistance and the promise of combination treatments for melanoma
- (2017) Merope Griffin et al. Oncotarget
- Distinct histone modifications denote early stress-induced drug tolerance in cancer
- (2017) Abdullah Al Emran et al. Oncotarget
- Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma
- (2017) Antoneicka L. Harris et al. Oncotarget
- Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
- (2016) Michael P. Smith et al. CANCER CELL
- Neurofibromatosis type 1 (NF1 ) gene: Beyond café au lait spots and dermal neurofibromas
- (2016) Sirkku Peltonen et al. EXPERIMENTAL DERMATOLOGY
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
- (2016) Simona Caporali et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- RASopathy Gene Mutations in Melanoma
- (2016) Ruth Halaban et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR
- (2016) Goran Micevic et al. Cell Reports
- Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2016) Vidhu Sharma et al. eLife
- Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
- (2015) M. A. Wilson et al. CLINICAL CANCER RESEARCH
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
- (2015) Douglas B. Johnson et al. EUROPEAN JOURNAL OF CANCER
- The DNA methylation landscape of human melanoma
- (2015) Seung-Gi Jin et al. GENOMICS
- Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
- (2015) Lawrence N. Kwong et al. JOURNAL OF CLINICAL INVESTIGATION
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
- (2015) Michael Krauthammer et al. NATURE GENETICS
- Recurrent inactivating RASA2 mutations in melanoma
- (2015) Rand Arafeh et al. NATURE GENETICS
- In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells
- (2015) Jennifer Allouche et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
- (2015) Francesco Spagnolo et al. OncoTargets and Therapy
- BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
- (2015) Caterina Chiappetta et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
- (2015) Ryan B. Corcoran et al. Oncotarget
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- A stress-induced early innate response causes multidrug tolerance in melanoma
- (2014) D Ravindran Menon et al. ONCOGENE
- UV Signature Mutations
- (2014) Douglas E. Brash PHOTOCHEMISTRY AND PHOTOBIOLOGY
- Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway
- (2014) Alexander Gross et al. Targeted Oncology
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2014) David Blum et al. eLife
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
- (2013) E. Romano et al. CLINICAL CANCER RESEARCH
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
- (2013) K. L. Nathanson et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600ETumors
- (2013) Meghna Das Thakur et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- The Akt signaling pathway
- (2012) SubbaRao V. Madhunapantula et al. CANCER BIOLOGY & THERAPY
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Molecular biology of melanoma
- (2012) Julie M. Swick et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Elucidating Distinct Roles for NF1 in Melanomagenesis
- (2012) Ophélia Maertens et al. Cancer Discovery
- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
- (2011) Inna V. Fedorenko et al. BIOCHEMICAL PHARMACOLOGY
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Epigenetics in Alternative Pre-mRNA Splicing
- (2011) Reini F. Luco et al. CELL
- Genetic alterations of PTEN in human melanoma
- (2011) Almass-Houd Aguissa-Touré et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
- (2010) Alexander Roesch et al. CELL
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search